CY1125073T1 - Ενωση πυριμιδινης - Google Patents
Ενωση πυριμιδινηςInfo
- Publication number
- CY1125073T1 CY1125073T1 CY20211101091T CY211101091T CY1125073T1 CY 1125073 T1 CY1125073 T1 CY 1125073T1 CY 20211101091 T CY20211101091 T CY 20211101091T CY 211101091 T CY211101091 T CY 211101091T CY 1125073 T1 CY1125073 T1 CY 1125073T1
- Authority
- CY
- Cyprus
- Prior art keywords
- seizure
- pyrimidine compound
- formula
- diagnosis
- prevention
- Prior art date
Links
- -1 PYRIMIDINE COMPOUND Chemical class 0.000 title abstract 2
- 206010010904 Convulsion Diseases 0.000 abstract 6
- 208000002091 Febrile Seizures Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010016284 febrile convulsion Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000005809 status epilepticus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει μία καινοφανή ένωση πυριμιδίνης που παριστάνεται με τον Τύπο [1] και ένα άλας αυτής: [στον Τύπο, τα σύμβολα είναι όπως ορίζεται στην προδιαγραφή], η οποία είναι χρήσιμη για αντιμετώπιση, πρόληψη και/ή διάγνωση κρίσης και τα συναφή σε νόσο που εμπλέκει επιληπτική κρίση ή σπασμωδική κρίση (περιλαμβάνοντας ανθεκτική σε πολλαπλά φάρμακα κρίση, ανθεκτική κρίση, οξεία συμπτωματική κρίση, εμπύρετη κρίση και επιληπτική κατάσταση), όπως επίσης και με μία ιατρική χρήση για αυτήν.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2017/020322 WO2018220762A1 (ja) | 2017-05-31 | 2017-05-31 | ピリミジン化合物 |
| PCT/JP2018/020997 WO2018221667A1 (en) | 2017-05-31 | 2018-05-31 | Pyrimidine compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125073T1 true CY1125073T1 (el) | 2023-03-24 |
Family
ID=62685028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211101091T CY1125073T1 (el) | 2017-05-31 | 2021-12-13 | Ενωση πυριμιδινης |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10800758B2 (el) |
| EP (1) | EP3630729B1 (el) |
| JP (1) | JP6739653B2 (el) |
| KR (1) | KR20200011962A (el) |
| CN (1) | CN110603248B (el) |
| AU (1) | AU2018277949B2 (el) |
| BR (1) | BR112019023988A2 (el) |
| CA (1) | CA3064176A1 (el) |
| CY (1) | CY1125073T1 (el) |
| DK (1) | DK3630729T3 (el) |
| EA (1) | EA038907B1 (el) |
| ES (1) | ES2901452T3 (el) |
| HR (1) | HRP20211913T1 (el) |
| HU (1) | HUE056942T2 (el) |
| IL (1) | IL270579B2 (el) |
| LT (1) | LT3630729T (el) |
| MX (1) | MX2019014384A (el) |
| PH (1) | PH12019502639A1 (el) |
| PL (1) | PL3630729T3 (el) |
| PT (1) | PT3630729T (el) |
| SA (1) | SA519410563B1 (el) |
| SI (1) | SI3630729T1 (el) |
| TW (2) | TW202346283A (el) |
| WO (2) | WO2018220762A1 (el) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6870064B2 (ja) * | 2018-11-30 | 2021-05-12 | 大塚製薬株式会社 | ピリミジン化合物の医薬用途 |
| EP3887358A1 (en) * | 2018-11-30 | 2021-10-06 | Otsuka Pharmaceutical Co., Ltd. | Heterocyclic compounds for the treatment of epilepsy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004009559A2 (en) * | 2002-07-18 | 2004-01-29 | Queen's University At Kingston | Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents |
| EA019970B8 (ru) | 2009-12-11 | 2014-11-28 | Отифони Терапеутикс Лимитед | Производные имидазолидиндиона |
| MX2012008346A (es) * | 2010-01-25 | 2012-11-12 | Chdi Foundation Inc | Determinados inhibidores de cinurenina-3-monooxigenasa, composiciones farmceuticas y metodos de uso de los mismos. |
| BR112013013914B1 (pt) * | 2010-12-06 | 2021-10-26 | Autifony Therapeutics Limited | Compostos derivados de hidantoína úteis como inibidores de kv3, usos dos referidos compostos e composição farmacêutica compreendendo os mesmos |
| WO2012168710A1 (en) * | 2011-06-07 | 2012-12-13 | Autifony Therapeutics Limited | Hydantoin derivates as kv3 inhibitors |
| WO2013016488A1 (en) * | 2011-07-28 | 2013-01-31 | Celia Dominguez | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| KR20140098850A (ko) | 2011-12-06 | 2014-08-08 | 오티포니 세라피틱스 리미티드 | Kv3 억제제로서 유용한 하이단토인 유도체 |
| GB201521751D0 (en) * | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
-
2017
- 2017-05-31 WO PCT/JP2017/020322 patent/WO2018220762A1/ja active Application Filing
-
2018
- 2018-05-30 TW TW112129778A patent/TW202346283A/zh unknown
- 2018-05-30 TW TW107118471A patent/TWI808974B/zh active
- 2018-05-31 US US16/471,998 patent/US10800758B2/en active Active
- 2018-05-31 MX MX2019014384A patent/MX2019014384A/es unknown
- 2018-05-31 SI SI201830499T patent/SI3630729T1/sl unknown
- 2018-05-31 JP JP2019535398A patent/JP6739653B2/ja active Active
- 2018-05-31 EP EP18732930.5A patent/EP3630729B1/en active Active
- 2018-05-31 BR BR112019023988-0A patent/BR112019023988A2/pt unknown
- 2018-05-31 HR HRP20211913TT patent/HRP20211913T1/hr unknown
- 2018-05-31 CN CN201880030366.XA patent/CN110603248B/zh active Active
- 2018-05-31 AU AU2018277949A patent/AU2018277949B2/en active Active
- 2018-05-31 PL PL18732930T patent/PL3630729T3/pl unknown
- 2018-05-31 PT PT187329305T patent/PT3630729T/pt unknown
- 2018-05-31 EA EA201992831A patent/EA038907B1/ru unknown
- 2018-05-31 HU HUE18732930A patent/HUE056942T2/hu unknown
- 2018-05-31 CA CA3064176A patent/CA3064176A1/en active Pending
- 2018-05-31 DK DK18732930.5T patent/DK3630729T3/da active
- 2018-05-31 ES ES18732930T patent/ES2901452T3/es active Active
- 2018-05-31 WO PCT/JP2018/020997 patent/WO2018221667A1/en active Application Filing
- 2018-05-31 KR KR1020197037748A patent/KR20200011962A/ko not_active Application Discontinuation
- 2018-05-31 LT LTEPPCT/JP2018/020997T patent/LT3630729T/lt unknown
-
2019
- 2019-11-12 IL IL270579A patent/IL270579B2/en unknown
- 2019-11-14 SA SA519410563A patent/SA519410563B1/ar unknown
- 2019-11-22 PH PH12019502639A patent/PH12019502639A1/en unknown
-
2020
- 2020-09-02 US US17/010,182 patent/US20200399245A1/en not_active Abandoned
-
2021
- 2021-12-13 CY CY20211101091T patent/CY1125073T1/el unknown
-
2022
- 2022-12-30 US US18/091,790 patent/US20230138411A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123353T1 (el) | Καινοφανης ενωση συμπυκνωμενης πυριμιδινης ή αλας εξ αυτης | |
| CY1121901T1 (el) | Ενωσεις τριαζολοπυριμιδινης και χρησεις αυτων | |
| CY1124537T1 (el) | Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα | |
| CY1122534T1 (el) | Νεες ενωσεις μεθυλο-πιπεριδινης χρησιμες για την αναστολη της μ1κροσωμικης συνθετασης-1 της προσταγλανδινης ε2 | |
| CY1121804T1 (el) | Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους | |
| CY1120073T1 (el) | Παραγωγα πυραζολο-αμινοπυριμιδινης ως ρυθμιστες της lrrk2 | |
| CY1122255T1 (el) | Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος | |
| CY1121549T1 (el) | Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων | |
| CY1122296T1 (el) | Θεραπευτικες ενωσεις χρησιμες για την προφυλακτικη ή θεραπευτικη αγωγη μολυνσης ιου ηiv | |
| CY1121792T1 (el) | Ετεροκυκλικη ενωση | |
| CY1125073T1 (el) | Ενωση πυριμιδινης | |
| CY1117200T1 (el) | Παραγωγα βενζυλαμινης ως αναστολεις καλλικρεϊνης πλασματος | |
| CY1121261T1 (el) | Ενωση τριαζινης και χρηση εξ αυτης για ιατρικους σκοπους | |
| CY1118681T1 (el) | Αναστολεις νεπριλυσινης | |
| CY1119620T1 (el) | Αναστολεις νεπριλυσινης | |
| CY1117776T1 (el) | Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες | |
| CY1121677T1 (el) | Ενωσεις διμεθυλοβενζοϊκου οξεος | |
| CY1118344T1 (el) | Αναστολεις απομεθυλασης-1 ειδικης για λυσινη και η χρηση αυτων | |
| CY1120173T1 (el) | Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης | |
| CY1118626T1 (el) | Παραγωγα μουσταρδας αζωτου | |
| CY1120111T1 (el) | Αντιβακτηριακα παραγωγα 2η-ινδαζολης | |
| CY1120836T1 (el) | Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| CY1118623T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινων ως αναστολεις της bace | |
| CY1119583T1 (el) | Φαινοξυαιθυλο παραγωγα κυκλικης αμινης και η δραστικοτητα τους ως τροποποιητες του ερ4 υποδοχεα | |
| CY1123494T1 (el) | Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2 |